Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indusatumab vedotin in GCC-positive gastric/GEJ cancer
NCT02202759Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of indusatumab vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Millennium Pharmaceuticals. Started Aug 2014; status: terminated.
02
Drugs
indusatumab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02202759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202759.